98 related articles for article (PubMed ID: 9262318)
1. Enhancing effects of monohexanoin and two other medium-chain glyceride vehicles on intestinal absorption of desmopressin (dDAVP).
Lundin PD; Bojrup M; Ljusberg-Wahren H; Weström BR; Lundin S
J Pharmacol Exp Ther; 1997 Aug; 282(2):585-90. PubMed ID: 9262318
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal absorption and plasma clearance rates of [D-Arg8]vasopressin analogues in the rat.
Lundin S; Folkesson HG; Pierzynovski SG; Bengtsson HI
Peptides; 1994; 15(5):809-14. PubMed ID: 7984498
[TBL] [Abstract][Full Text] [Related]
3. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).
Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931
[TBL] [Abstract][Full Text] [Related]
4. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers.
Sharma P; Varma MV; Chawla HP; Panchagnula R
Farmaco; 2005; 60(11-12):884-93. PubMed ID: 16226752
[TBL] [Abstract][Full Text] [Related]
5. Improved oral delivery of desmopressin via a novel vehicle: mucoadhesive submicron emulsion.
Ilan E; Amselem S; Weisspapir M; Schwarz J; Yogev A; Zawoznik E; Friedman D
Pharm Res; 1996 Jul; 13(7):1083-7. PubMed ID: 8842050
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates.
Wang J; Wu D; Shen WC
Pharm Res; 2002 May; 19(5):609-14. PubMed ID: 12069162
[TBL] [Abstract][Full Text] [Related]
7. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects.
Rittig S; Jensen AR; Jensen KT; Pedersen EB
Clin Endocrinol (Oxf); 1998 Feb; 48(2):235-41. PubMed ID: 9579238
[TBL] [Abstract][Full Text] [Related]
8. Different properties of the paracellular pathway account for the regional small intestinal permeability to the peptide desmopressin.
Pantzar N; Lundin S; Weström BR
J Pharm Sci; 1995 Oct; 84(10):1245-8. PubMed ID: 8801342
[TBL] [Abstract][Full Text] [Related]
9. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
Sharma P; Varma MV; Chawla HP; Panchagnula R
Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320
[TBL] [Abstract][Full Text] [Related]
10. Differences in transport rate of oxytocin and vasopressin analogues across proximal and distal isolated segments of the small intestine of the rat.
Lundin S; Pantzar N; Broeders A; Ohlin M; Weström BR
Pharm Res; 1991 Oct; 8(10):1274-80. PubMed ID: 1796046
[TBL] [Abstract][Full Text] [Related]
11. Estimation of absorption enhancement by medium-chain fatty acids in rat large intestine.
Higaki K; Yata T; Sone M; Ogawara K; Kimura T
Res Commun Mol Pathol Pharmacol; 2001; 109(3-4):231-40. PubMed ID: 11758652
[TBL] [Abstract][Full Text] [Related]
12. NTP Comparative Toxicology Studies of Corn Oil, Safflower Oil, and Tricaprylin (CAS Nos. 8001-30-7, 8001-23-8, and 538-23-8) in Male F344/N Rats as Vehicles for Gavage.
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Apr; 426():1-314. PubMed ID: 12616305
[TBL] [Abstract][Full Text] [Related]
13. Decreased passage of the nonapeptide dDAVP over the intestinal epithelium during development in the young rat.
Folkesson HG; Weström BR; Lundin S; Karlsson BW
Acta Physiol Scand; 1988 Jul; 133(3):283-8. PubMed ID: 3227922
[TBL] [Abstract][Full Text] [Related]
14. Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation.
Constantinides PP; Welzel G; Ellens H; Smith PL; Sturgis S; Yiv SH; Owen AB
Pharm Res; 1996 Feb; 13(2):210-5. PubMed ID: 8932438
[TBL] [Abstract][Full Text] [Related]
15. Absorption of an oxytocin antagonist (antocin) and a vasopressin analogue (dDAVP) through a standardized skin erosion in volunteers.
Lundin S; Svedman P; Höglund P; Jönsson K; Broeders A; Melin P
Pharm Res; 1995 Dec; 12(12):2024-9. PubMed ID: 8786983
[TBL] [Abstract][Full Text] [Related]
16. Microemulsions as transdermal drug delivery vehicles.
Kogan A; Garti N
Adv Colloid Interface Sci; 2006 Nov; 123-126():369-85. PubMed ID: 16843424
[TBL] [Abstract][Full Text] [Related]
17. Emulsion-based colloidal nanosystems for oral delivery of doxorubicin: improved intestinal paracellular absorption and alleviated cardiotoxicity.
Kim JE; Yoon IS; Cho HJ; Kim DH; Choi YH; Kim DD
Int J Pharm; 2014 Apr; 464(1-2):117-26. PubMed ID: 24463005
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cardiovascular reactivity to desmopressin in water-restricted rats: facilitatory role of immunosuppression.
Tyagi MG; Thomas M
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):619-24. PubMed ID: 10669908
[TBL] [Abstract][Full Text] [Related]
19. Self-micelle formation and the incorporation of lipid in the formulation affect the intestinal absorption of Panax notoginseng.
Xiong J; Guo J; Huang L; Meng B; Ping Q
Int J Pharm; 2008 Aug; 360(1-2):191-6. PubMed ID: 18502060
[TBL] [Abstract][Full Text] [Related]
20. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats.
Dahan A; Hoffman A
Eur J Pharm Biopharm; 2007 Aug; 67(1):96-105. PubMed ID: 17329087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
